Immunosuppressants drugs for COVID-19: living meta-analysis of clinical studies

Table Graph

Immunosuppressants drugs - versus control - for COVID-19 severe or critically pdf xlsx method abbreviations

Outcome	Relative effect 95%CI	Trt. better when	I2	k (RCT/OBS)	Bayesian probability	Overall ROB	Publication bias	Degree of certainty	Endpoint importance	Published MA
efficacy endpoints 00
death D28	0.90 [0.64, 1.26]	< 1	28%	8 studies (10/-)	73.7 %	some concern	not evaluable	moderate	crucial	-
death or transfer to ICU	0.93 [0.87, 0.99]	< 1	0%	1 study (-/1)	98.6 %	NA	not evaluable		crucial	-
deaths	0.87 [0.70, 1.09]	< 1	16%	12 studies (17/-)	89.0 %	some concern	low	moderate	crucial	-
deaths (time to event analysis only)	1.04 [0.78, 1.38]	< 1	0%	3 studies (3/-)	39.8 %	some concern	not evaluable	moderate	crucial	-
clinical deterioration	0.56 [0.26, 1.20]	< 1	0%	1 study (1/-)	93.1 %	NA	not evaluable		important	-
clinical improvement	1.38 [1.04, 1.82]	> 1	40%	6 studies (7/-)	98.8 %	some concern	not evaluable	moderate	important	-
clinical improvement (14-day)	1.97 [0.95, 4.09]	> 1	0%	1 study (2/-)	96.6 %	NA	not evaluable		important	-
clinical improvement (28-day)	1.33 [0.95, 1.87]	> 1	0%	4 studies (4/-)	95.3 %	some concern	not evaluable	moderate	important	-
clinical improvement (time to event analysis only)	1.09 [0.87, 1.35]	> 1	0%	2 studies (2/-)	76.9 %	some concern	not evaluable	moderate	important	-
death or ventilation	0.96 [0.65, 1.43]	< 1	26%	3 studies (3/-)	57.8 %	some concern	not evaluable	moderate	important	-
hospital discharge	0.97 [0.79, 1.20]	> 1	0%	1 study (1/-)	38.9 %	NA	not evaluable		important	-
mechanical ventilation	0.36 [0.09, 1.48]	< 1	31%	3 studies (4/-)	92.1 %	some concern	not evaluable	moderate	important	-
ICU admission	0.48 [0.25, 0.94]	< 1	0%	1 study (2/-)	98.4 %	NA	not evaluable		non important	-
recovery	1.30 [0.64, 2.66]	> 1	9%	2 studies (2/-)	76.5 %	low	not evaluable	high	non important	-
safety endpoints 00
related AE (TRAE)	1.26 [0.14, 11.07]	< 1	0%	2 studies (2/-)	41.9 %	some concern	not evaluable	moderate	important	-
serious adverse events	0.99 [0.77, 1.28]	< 1	16%	6 studies (6/-)	52.7 %	some concern	serious	moderate	important	-
superinfection	3.27 [1.66, 6.43]	< 1	0%	1 study (-/1)	0.0 %	NA	not evaluable		important	-
acute kidney injury	0.43 [0.14, 1.34]	< 1	0%	1 study (-/1)	92.7 %	NA	not evaluable		non important	-
adverse events	1.14 [0.87, 1.50]	< 1	22%	7 studies (7/-)	16.7 %	some concern	not evaluable	moderate	non important	-
arrhythmia	0.16 [0.03, 0.90]	< 1	0%	1 study (-/1)	98.1 %	NA	not evaluable		non important	-
elevated liver enzymes	0.52 [0.18, 1.51]	< 1	0%	1 study (-/1)	88.5 %	NA	not evaluable		non important	-
Myocardial infarction	0.87 [0.19, 3.92]	< 1	0%	1 study (-/1)	57.2 %	NA	not evaluable		non important	-
venous thromboembolism	5.23 [0.42, 65.62]	< 1	0%	1 study (-/1)	10.2 %	NA	not evaluable		non important	-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.

Immunosuppressants drugs - versus control - for COVID-19 severe or critically pdf xlsx method abbreviations

efficacy endpoints 00

safety endpoints 00